-
Dec.012014NEWS
HanAll is Entering into the 60 Billion KRW Market with Peptic Ulcer Drug “Wibis Tab”
HanAll is Entering into the 60 Billion KRW Market with Peptic Ulcer Drug “Wibis Tab”
-
Nov.212014NEWS
HanAll Biopharma Records Surplus for Three Consecutive Quarter
HanAll Biopharma Records Surplus for Three Consecutive Quarter
-
Jul.102014NEWS
HanAll Completed the CGMP-class Production Plant for Cutting-edge Solid Formula
HanAll Completed the CGMP-class Production Plant for Cutting-edge Solid Formula
-
May.232014NEWS
HanAll Biopharma, Achieving Net Income of 540M KRW to Turn into Surplus
HanAll Biopharma, Achieving Net Income of 540M KRW to Turn into Surplus
-
Apr.272014NEWS
Hanall Biopharma, Completed the Clinical Trial Phase 1 of \'HL036\', New Medicine for Dry Eye Disease
Hanall Biopharma, Completed the Clinical Trial Phase 1 of \'HL036\', New Medicine for Dry Eye Diseas